Skip to content

ADC Therapeutics SA

ADCT

CIK 0001771910

← back to feed
Revenue (TTM)
$71.27M
−7.8% YoY Q1 Apr 2026
Net Income (TTM)
−$169.18M
+9.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.37
+30.9% YoY Q1 Apr 2026
Gross Margin
91.9%
Q1 Apr 2026
Operating Margin
-180.8%
Q1 Apr 2026
Net Margin
-237.4%
Q1 Apr 2026
Free Cash Flow (TTM)
−$147.37M
Q1 Apr 2026
Cash
$231.01M
Q1 Apr 2026
Total Debt
$4.64M
Q1 Apr 2026
Shares Outstanding
127.19M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings